Dyne Therapeutics, Inc.
DYN Nasdaq
SEC CIK 1818794
Follow Dyne Therapeutics
Weekly email: filings, results
Net income
−$193.6M
−79.1% vs same quarter last year
EPS, diluted
−$1.06
−39.5% vs same quarter last year
Operating cash flow
−$177.5M
−95.5% vs same quarter last year
Operating income
−$197.1M
−73% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$446.2 |
| FY24 | −$317.4 |
| FY23 | −$235.9 |
| FY22 | −$168.1 |
| FY21 | −$149.3M |
| FY20 | −$59.4M |
| FY19 | −$14.9M |
| FY18 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$405.1M |
| FY24 | −$294.7M |
| FY23 | −$188.9M |
| FY22 | −$156.7M |
| FY21 | −$123.2M |
| FY20 | −$47.7M |
| FY19 | −$13.5M |
| FY18 | - |